A Multicenter, Prospective, Open-label Study to Evaluate the Pharmacokinetics and Safety of Gadoquatrane in Pediatric Participants (From Birth to <18 Years) Undergoing Contrast-enhanced Magnetic Resonance Imaging (CE-MRI)
Latest Information Update: 16 Jan 2025
At a glance
- Drugs Gadoquatrane (Primary)
- Indications CNS disorders
- Focus Pharmacokinetics; Registrational
- Acronyms Quanti Pediatric
- Sponsors Bayer
Most Recent Events
- 10 Jan 2025 According to Bayer Media Release, Bayer plans to submit a comprehensive data package which will include the QUANTI study results to health authorities worldwide to secure marketing authorization.
- 10 Jan 2025 Results presented in the Bayer Media Release.
- 29 Oct 2024 Status changed from recruiting to completed.